Sab Biotherapeutics to Present Data on SAB-142 at ATTD-Asia Conference

Sab Biotherapeutics will present data on its lead program, SAB-142, at the Asian Conference on Innovative Therapies for Diabetes Management. The presentations will showcase progress in the development of SAB-142, a potentially best-in-class immunotherapy for delaying the progression of Type 1 Diabetes (T1D) in new-onset Stage 3 patients. The data to be presented includes Phase 1 study results demonstrating the multi-specific mechanism of action and immunomodulation without sustained lymphodepletion following dosing of SAB-142.